小儿EB病毒阳性侵袭性自然杀伤细胞白血病的成功治疗
Successful Treatment of Pediatric Epstein-Barr Virus-positive Aggressive Natural Killer-Cell Leukemia.
作者信息
Kim Bo Kyung, Hong Kyung Taek, Kang Hyoung Jin, An Hong Yul, Choi Jung Yoon, Hong Che Ry, Park Kyung Duk, Lee Dong Soon, Shin Hee Young
机构信息
Department of Pediatrics, Seoul National University College of Medicine, Seoul National University Cancer Research Institute.
Department of Laboratory Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
出版信息
J Pediatr Hematol Oncol. 2019 Jul;41(5):e336-e337. doi: 10.1097/MPH.0000000000001237.
Epstein-Barr virus (EBV)-positive aggressive natural killer-cell leukemia (ANKL) is a rare malignancy of mature natural killer cells, with a very poor survival rate. Patients have a rapidly declining clinical course and a poor prognosis, with a median survival of only a few months. Herein, we describe a 16-year-old boy who was diagnosed with EBV-positive ANKL and successfully treated using combination chemotherapy and a subsequent allogeneic hematopoietic stem cell transplantation (alloHSCT). The patient is disease free 4 years and 9 months after alloHSCT. Thus, combination chemotherapy followed by alloHSCT seems to be a promising therapeutic option for EBV-positive ANKL.
爱泼斯坦-巴尔病毒（EBV）阳性侵袭性自然杀伤细胞白血病（ANKL）是一种罕见的成熟自然杀伤细胞恶性肿瘤，生存率极低。患者临床病程迅速恶化，预后不良，中位生存期仅几个月。在此，我们描述一名16岁男孩，他被诊断为EBV阳性ANKL，并通过联合化疗及随后的异基因造血干细胞移植（alloHSCT）成功治愈。该患者在alloHSCT后4年9个月无病生存。因此，联合化疗后行alloHSCT似乎是EBV阳性ANKL一种有前景的治疗选择。
Zotero 插件